Press

Hip and dental implant operations are routine. But not entirely risk-free. They may result in inflammation that is difficult to control with oral or intravenous antibiotics. In such cases, the implant will probably need to be replaced. Fraunhofer researchers can now apply a precisely matched drug directly to the replacement implant while significantly increasing the effectiveness of the antibiotic via a synergism with silver ions. Their research will be on display at the MEDICA and COMPAMED trade fairs from November 12 to 15, 2018 in Düsseldorf (Hall 8a, Stand P13).

On August 1st and 2nd, scientists of the Chilean- German project "MoMaPo" met at the Fraunhofer IME in Aachen. The aim of the binational cooperation project "MoMaPo" is the identification of molecular markers for an increased anthocyanin content in potato tubers. Molecular markers are a tool of modern breeding. With their help, the breeders can succeed in developing new varieties in a shorter time compared to classical breeding.

Life sciences startup LenioBio GmbH and the Fraunhofer IME announced today the signing of an exclusive license agreement that allows LenioBio to utilize Fraunhofer’s proprietary vector solution and technology for the cryopreservation of cell-free lysates. The optimized vector solution and cryopreservation technology from Fraunhofer IME has been specifically developed to meet the wide application areas LenioBio is targeting. With the addition of the Fraunhofer IME license, LenioBio is extending the patent family covering this innovative cell-free system.

Jacobs University Bremen and the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, today announce their intention to set up a new strategic collaboration to establish joint research projects in the area of antibiotic drug discovery and promote the exchange of students, researchers and educators between the institutions.

The Fraunhofer IME presented a living exhibit and it`s digital twin at the joint Fraunhofer booth “Future Factory” at the Hanover Trade Fair 2018.

The Fraunhofer Institute for Molecular Biology and Applied Ecology IME participates in the EU-funded NEWCOTIANA project a research and innovation action that combines several new plant breeding techniques to produce medical and cosmetic products in plants.

The interdisciplinary consortium HiPSTAR tries to decipher the molecular mechanisms leading to Morbus Alzheimer. In particular, pathological alterations at the blood-brain-barrier are in the focus of this applied research project. The long-term goal of this collaborative effort is the development of new drugs and therapies targeting this predominant form of dementia. The project is coordinated by the University of Würzburg (Medical Faculty, Department of Tissue Engineering and Regenerative Medicine, TERM), and the Fraunhofer Institute for Molecular Biology and Applied Ecology, ScreeningPort, is a partner in the consortium. The German Ministry for Education and Research (Bundesministerium für Bildung und Forschung, BMBF) funds this project with an overall budget of 1.7 million Euro.

Hamburg. Human stem cells, which can be produced from mature cells by dialing back their developmental programming - so-called "induced pluripotent stem cells (iPS cells)" - have enormous potential for regenerative medicine as well as for the research and development of new therapeutics. To ensure the development of better drug candidates in the field of patient-derived iPS cells, Evotec AG and the Fraunhofer Institute for Molecular Biology and Applied Ecology IME are entering into a strategic alliance.

Los Angeles, CA, Fraunhofer IME, Uskudar University , the Society for Brain Mapping and Therapeutics (SBMT), Brain Mapping Foundation (BMF), National Center for NanoBioElectronic (NCNBE) have come together in Hamburg, Germany during the G20 Summit to expand global cooperation and partnership on clinical translational neuroscience through Neuroscience-20 (N20) Initiative. The scientists call for global collaboration, partnership, data-sharing, and more allocation of funds to combat enormous economical and human costs of neurological disorders world wide

Strategic collaboration between Hamburg and Groningen: In order to facilitate drug discovery and biomarker development within the theme Healthy Ageing, Fraunhofer IME ScreeningPort (Hamburg) and the European Research Institute for the Biology of Ageing ERIBA (University Medical Center Groningen, University of Groningen), have formed a strategic alliance. The initiative is supported by grants from the cities of Hamburg and Groningen.